Nureca Limited returned to profitability in the first quarter of FY27, reporting a consolidated net profit of ₹3.07 crore for the period ended June 30, 2026. This marks a recovery from the net loss of ₹6 crore posted in the quarter ended March 31, 2026. Revenue from operations rose to ₹40.34 crore, compared to ₹35.4 crore in the previous quarter, driven by the company's home healthcare and wellness products segment. The company achieved its highest quarterly sales and profitability in the last 16 quarters.

Financial Performance Overview

The Board of Directors approved the unaudited financial results at a meeting held on July 21, 2026. On a consolidated basis, the company reported an EBITDA of ₹5.2 crore for the quarter, a significant increase from the negative EBITDA of ₹4.7 crore in the previous quarter. Profit before tax stood at ₹4.43 crore. Gross margin was 39%, while operating margin improved to 8.7%. The Gross Merchandise Value (GMV) for the quarter was ₹51.8 crore, up from ₹49.7 crore in Q4 FY26. Nureca remains debt-free with net cash and investments of ₹110 crore.

Consolidated Results (Q1FY27)

Operational Highlights

The company reported an operating profit of ₹3.5 crore for Q1FY27, compared to ₹2.6 crore in the preceding quarter. On a standalone basis, the company reported a net profit of ₹2.43 crore for Q1FY27, reversing the net loss of ₹6.63 crore in Q4 FY26. Standalone revenue from operations increased to ₹40.40 crore from ₹35.41 crore in the quarter ended March 31, 2026.

Business Segment Performance

Nureca operates in a single business segment focused on home healthcare and wellness products. The sales mix for Q1 FY27 was predominantly online at 87.6%, with offline retail accounting for 12.4%. Online sales increased by 16% year-on-year, while offline retail revenue grew by 57% year-on-year. The company continues to expand its manufacturing capabilities, with revenue from in-house manufactured products contributing 27% in Q1 FY27 compared to 26% in FY26.

Nureca Limited disclosed that its promoter group's shareholding increased to 68.09% following a recent buyback of equity shares. The buyback, which opened on December 18, 2025, and closed on December 24, 2025, led to the extinguishment of shares on January 07, 2026. Consequently, the promoters' equity share capital and voting rights increased, although the number of shares held by them remained unchanged at 64,97,176.

The disclosures were submitted to the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 29(1) and 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquirers included Saurabh Goyal, Aryan Goyal, Payal Goyal, Smita Goyal, and Nectar Biopharma Private Limited.

The equity share capital of the company before the acquisition was 100,001,750, which reduced to 95,419,200 after the extinguishment of shares. The total diluted share capital post-acquisition stood at 95,419,200. The public shareholding decreased by 4,58,255 shares, bringing the public holding down to 31.91%.

Shareholding Pattern

The following table details the shareholding of the promoter and promoter group before and after the buyback: